1. Market Research
  2. > Pathology
About 300 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Burkitt Lymphoma Global Clinical Trials Review, H1, 2020

  • $ 2500
  • February 2020
  • 311 pages

Burkitt Lymphoma Global Clinical Trials Review, H##, 2020 H e a l t h c a r e H e a l t h c a r e REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: FEB 2020 LIST OF TABLES LIST OF FIGURES Burkitt Lymphoma Global Clinical Trials Review, H##, 2020 outlines clinical trials in Burkitt

  • Blood Disease
  • Clinical Trial
  • Immunotherapy
  • Lymphoma
  • Therapy

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • August 2019
  • 228 pages

So the CAR T, for example, represents a cure of lymphoma and leukemia.

  • Blood Disease
  • Lymphoma
  • Pathology
  • Therapy
  • Novo Nordisk Group

Burkitt Lymphoma Global Clinical Trials Review, H2, 2018

  • $ 2500
  • December 2018
  • 303 pages

Burkitt Lymphoma Global Clinical Trials Review, H##, 2018 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: DEC 2018 LIST OF TABLES LIST OF FIGURES Burkitt Lymphoma Global Clinical Trials Review, H##, 2018 outlines clinical trials in Burkitt

  • Blood Disease
  • Clinical Trial
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Global Clinical Trials Review, H2, 2018

  • $ 2500
  • September 2018
  • 423 pages

The hematologic cancers being studied in the trial include multiple myeloma (MM), chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/ SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and potential

  • Blood Disease
  • Clinical Trial
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody

Anaplastic Large Cell Lymphoma (ALCL) Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018
  • 284 pages

Anaplastic Large Cell Lymphoma (ALCL) Global Clinical Trials Review, H##, 2018 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: OCT 2018 LIST OF TABLES LIST OF FIGURES Anaplastic Large Cell Lymphoma (ALCL) Global Clinical Trials Review, H##, 2018 outlines cl

  • Blood Disease
  • Clinical Trial
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody

Global Bone Marrow Transplant Market 2017-2021

  • $ 2500
  • July 2017
  • 78 pages

The various malignant tumors are further classified into sarcomas, carcinomas, and lymphomas.

  • Blood Disease
  • Lymphoma
  • Specialty Hospital
  • Transplantation
  • Merck & Co., Inc.

Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2018

  • $ 2500
  • March 2018
  • 147 pages

Natural Killer Cell Lymphomas Global Clinical Trials Review, H##, 2018 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: MAR 2018 LIST OF TABLES Natural Killer Cell Lymphomas Global Clinical Trials Review, H##, 2018 outlines clinical trials in Natural Killer

  • Blood Disease
  • Cancer
  • Cell Therapy
  • Lymphoma
  • Oncology

Myelodysplastic Syndromes: Opportunity Analysis and Forecasts to 2028

  • $ 10995
  • May 2020
  • 193 pages

GAMIDA HAS AN ONGOING PHASE III, MULTICENTER, RANDOMIZED, REGISTRATIONAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF TRANSPLANTATION WITH OMIDUBICEL VERSUS TRADITIONAL UCBT IN PATIENTS WITH LEUKEMIA, LYMPHOMA, AND KOLs noted that patients with TP##mutant MDS have exceptionally poor prognose

  • Blood Disease
  • Lymphoma
  • Therapy
  • United States
  • Demand

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

  • $ 513
  • November 2016
  • 71 pages

REVLIMID IS NOT APPROVED FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA.

  • Blood Disease
  • Lymphoma
  • Therapy
  • United States
  • Celgene Corporation

Emerging Gene Therapies - Trends within the Technological, Clinical, Regulatory and Competitive Landscape

  • $ 2995
  • January 2019
  • 99 pages

In October 2017, Gilead acquired Kite Pharma for Yescarta, the first CAR-T product for B-cell lymphoma.

  • Blood Disease
  • Gene Therapy
  • Lymphoma
  • Medical Biotechnology
  • Therapy

Blood Disease Drugs Industry Forecasts - China Focus

  • $ 1800
  • October 2019
  • 145 pages

Blood Disease Drugs Industry Forecasts - China Focus Published by Asia Market Info and Dev Co.

  • Blood Disease
  • Leukemia
  • Lymphoma
  • Therapy
  • China

Follicular Lymphoma Global Clinical Trials Review, H2, 2017

  • $ 2500
  • August 2017
  • 750 pages

Kite is currently enrolling adult patients with relapsed/ refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL) at multiple EU medical centers.

  • Blood Disease
  • Clinical Trial
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 2750
  • September 2016
  • 504 pages

BY TYPE, 2011-2016 (NO. ) ## FIGURE ## ESTIMATED NEW CASES OF LYMPHOMA IN THE U. S.

  • Blood Disease
  • Cancer
  • Lymphoma
  • Pathology
  • World

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H2, 2017

  • $ 2500
  • July 2017
  • 849 pages

B-cell malignancies, like chronic lymphocytic leukemia, Waldenstrom' s macroglobulinemia, diffuse large B-cell lymphoma and mantle cell lymphoma are driven by BTK.

  • Blood Disease
  • Clinical Trial
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody

Blood Disease Drugs Markets in China

  • $ 4000
  • October 2019
  • 290 pages

Blood Disease Drugs Markets in China Published by Asia Market Info and Dev Co.

  • Blood Disease
  • Lymphoma
  • Pharmaceutical
  • China
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

Global Next-Generation Biologics Market 2016-2020

  • $ 2500
  • November 2016
  • 124 pages

Its R& D division focuses on developing innovative drugs for the treatment of malignant lymphoma.

  • Blood Disease
  • Cell Therapy
  • Lymphoma
  • Regenerative Medicine
  • Seattle Genetics, Inc.

Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need

  • $ 6995
  • August 2017
  • 79 pages

FRONTIER PHARMA Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need Published: August 2017 Report Code: GBIHC##MR www. gbiresearch. com © GBI Research.

  • Blood Disease
  • Pathology
  • Pharmaceutical
  • Therapy
  • Omeros Corporation

Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 178 pages

IT WAS UNDER DEVELOPMENT FOR THE TREATMENT OF MANTLE CELL LYMPHOMA.

  • Blood Disease
  • Hospital
  • Lymphoma
  • Targeted Therapy
  • Therapy

Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

  • $ 4995
  • March 2017
  • 1 pages

lymphoma invasion and metastasis inducing protein ## Granulocyte colony stimulating factor receptor Cannabinoid receptor ## Mu type opioid receptor Recombinant protein Synthetic peptide Small molecule Cystathionine gamma lyase Preclinical Kindolor Lohocla Chemotherapy induced pain doxorubicin

  • Blood Disease
  • Cancer
  • Lymphoma
  • Therapy
  • Amgen Inc.

Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 181 pages

IT WAS UNDER DEVELOPMENT FOR THE TREATMENT OF MANTLE CELL LYMPHOMA.

  • Blood Disease
  • Hospital
  • Lymphoma
  • Targeted Therapy
  • Therapy
View report >

Healthcare Demographic Impact in the US

  • June 2019
  • 50 pages

Jude patients in FY2016-2018 (##. ##%), followed by leukemia (##. ##%), and lymphomas (##. ##%) (Figure ##).

  • Blood Disease
  • Healthcare
  • HIV AIDS
  • Lymphoma
  • United States

Global Therapy Market January 2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on